Charles Marie Dumontet

List of Publications by Year
in descending order

273	19,950	16411 64	12233 133
papers	citations	h-index	g-index

285	285	285	24546
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics, 2022, 30, 474-479.	1.4	5
2	Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. Molecular Pharmaceutics, 2022, 19, 929-935.	2.3	4
3	Common gene variants within 3â€²â€untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	2.3	3
4	Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation. Cellular Oncology (Dordrecht), 2021, 44, 151-165.	2.1	5
5	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54
6	Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1â€“XPF-mediated DNA repair. Cancer Chemotherapy and Pharmacology, 2021, 87, 259-267.	1.1	7
7	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153.	1.4	2
8	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	2.3	3
9	Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals, 2021, 14, 247.	1.7	27
10	Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal, 2021, 11, 74.	2.8	10
11	CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129842.	1.1	4
12	Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia. Leukemia and Lymphoma, 2021, , 1-6.	0.6	1
13	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	5.5	34
14	Transcriptional and Metabolic Investigation in 5â€²-Nucleotidase Deficient Cancer Cell Lines. Cells, 2021, 10, 2918.	1.8	2
15	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. Molecular Cancer Therapeutics, 2020, 19, 2371-2381.	1.9	3
16	Antibodyâ€“Drug Conjugates: The Last Decade. Pharmaceuticals, 2020, 13, 245.	1.7	207
17	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. Frontiers in Immunology, 2020, 11, 492.	2.2	40
18	Characterization of Tâ€DM1â€resistant breast cancer cells. Pharmacology Research and Perspectives, 2020, 8, e00617.	1.1	9

#	Article	IF	Citations
19	BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	3.2	37
20	Targeting the nucleotide metabolism proteins of the NUDIX family and SAMHD1 in cancer. Current Medicinal Chemistry, 2020, 28, 4088-4116.	1.2	2
21	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology, 2019, 10, 1943.	2.2	22
22	Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chemical Science, 2019, 10, 4048-4053.	3.7	59
23	The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. Leukemia and Lymphoma, 2019, 60, 2572-2575.	0.6	4
24	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia, 2019, 33, 2324-2330.	3.3	33
25	In vitromodulation of multidrug resistance by pregnane steroids andin vivoinhibition of tumour development by 7Î±-OBz-11Î±(R)-OTHP-5Î²-pregnanedione in K562/R7 and H295R cell xenografts. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 684-691.	2.5	4
26	Lead optimization and biological evaluation of fragment-based cN-II inhibitors. European Journal of Medicinal Chemistry, 2019, 168, 28-44.	2.6	9
27	Engineering therapeutic bispecific antibodies using CrossMab technology. Methods, 2019, 154, 21-31.	1.9	89
28	Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault proteinÂ(MVP). Breast Cancer Research, 2019, 21, 7.	2.2	93
29	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	0.6	11
30	Granulocyte Colony-Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part I): Synthesis and Biodistribution Studies. Bioconjugate Chemistry, 2018, 29, 795-803.	1.8	4
31	Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and In Vivo Antitumor Efficacy in Combination with Rituximab. Bioconjugate Chemistry, 2018, 29, 804-812.	1.8	3
32	Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.4	56
33	Functions of the multiâ€interacting protein KIDINS220/ARMS in cancer and other pathologies. Genes Chromosomes and Cancer, 2018, 57, 114-122.	1.5	8
34	The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, 2018, 132, 2775-2777.	0.6	12
35	Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. Transfusion, 2018, 58, 2635-2644.	0.8	11
36	Piperidinyl-embeded chalcones possessing anti PI3KÎ´ inhibitory properties exhibit anti-atopic properties in preclinical models. European Journal of Medicinal Chemistry, 2018, 158, 405-413.	2.6	4

#	Article	IF	Citations
37	The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Frontiers in Immunology, 2018, 9, 2100.	2.2	94
38	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	3.3	53
39	Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology, 2018, 102, 161-168.	0.9	8
40	Real life management of patients hospitalized with multiple myeloma in France. PLoS ONE, 2018, 13, e0196596.	1.1	8
41	CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. European Journal of Medicinal Chemistry, 2018, 157, 1051-1055.	2.6	24
42	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	1.5	30
43	Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. Oncotarget, 2018, 9, 21141-21155.	0.8	17
44	Alteration of Natural Killer cell phenotype and function in obese individuals. Clinical Immunology, 2017, 177, 12-17.	1.4	93
45	Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents. Molecular Pharmaceutics, 2017, 14, 441-447.	2.3	17
46	TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). Leukemia Research, 2017, 56, 21-28.	0.4	6
47	Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LCâ€“MS/MS in human cancer cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1053, 101-110.	1.2	5
48	Reply to â€œClinical and therapeutic implications of <scp>BRAF</scp> mutation heterogeneity in metastatic melanomaâ€•by Mesbah Ardakani etÂal.. Pigment Cell and Melanoma Research, 2017, 30, 498-500.	1.5	3
49	Strategies and challenges for the next generation of antibodyâ€“drug conjugates. Nature Reviews Drug Discovery, 2017, 16, 315-337.	21.5	1,527
50	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
51	Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin. International Journal of Molecular Sciences, 2017, 18, 1676.	1.8	16
52	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. PLoS ONE, 2017, 12, e0170160.	1.1	25
53	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World Journal of Stem Cells, 2017, 9, 227-234.	1.3	31
54	The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget, 2017, 8, 57622-57641.	0.8	135

#	Article	IF	Citations
55	The cytosolic 5â€²-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget, 2017, 8, 67380-67393.	0.8	13
56	Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget, 2016, 7, 2889-2909.	0.8	19
57	Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation. Beilstein Journal of Organic Chemistry, 2016, 12, 1476-1486.	1.3	14
58	Stably transfected adherent cancer cell models with decreased expression of 5â€²-nucleotidase cN-II. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 604-612.	0.4	7
59	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 4350-4355.	3.2	38
60	Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. Steroids, 2016, 116, 5-12.	0.8	9
61	Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents. Journal of Visualized Experiments, 2016, , e53846.	0.2	7
62	A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells. Molecular Cancer Therapeutics, 2016, 15, 1890-1899.	1.9	28
63	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Molecular Cancer Therapeutics, 2016, 15, 1238-1247.	1.9	11
64	The druggability of intracellular nucleotide-degrading enzymes. Cancer Chemotherapy and Pharmacology, 2016, 77, 883-893.	1.1	16
65	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
66	Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Research, 2015, 17, 57.	2.2	93
67	Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. PLoS ONE, 2015, 10, e0134247.	1.1	19
68	Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica, 2015, 100, e204-e206.	1.7	14
69	Synthesis of New Steroidal Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance and Biological Evaluation on K562/R7 Erythroleukemia Cells. Journal of Medicinal Chemistry, 2015, 58, 1832-1845.	2.9	12
70	Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. MAbs, 2015, 7, 192-198.	2.6	29
71	Determination of the enzymatic activity of cytosolic 5â€²-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. Analytical and Bioanalytical Chemistry, 2015, 407, 5747-5758.	1.9	20
72	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38

#	Article	IF	Citations
73	Higher percentage of CD34 + CD38â˜ cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 622-629.	0.6	9
74	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11
75	Identification of Noncompetitive Inhibitors of Cytosolic 5â€²-Nucleotidase II Using a Fragment-Based Approach. Journal of Medicinal Chemistry, 2015, 58, 9680-9696.	2.9	18
76	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	2.3	30
77	Cytosolic 5â€™-Nucleotidase II Interacts with the Leucin Rich Repeat of NLR Family Member Ipaf. PLoS ONE, 2015, 10, e0121525.	1.1	17
78	Rare Circulating Cells in Familial WaldenstrÃ¶m Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. PLoS ONE, 2015, 10, e0136505.	1.1	6
79	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 855-862.	0.6	16
80	2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models. Molecular Imaging and Biology, 2014, 16, 118-126.	1.3	14
81	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associationsâ€”An Extensive Replication of the Associations from the Candidate Gene Era. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 670-674.	1.1	13
82	Structureâ€“activity relationships of Î²-hydroxyphosphonate nucleoside analogues as cytosolic 5â€²-nucleotidase II potential inhibitors: Synthesis, inÂvitro evaluation and molecular modeling studies. European Journal of Medicinal Chemistry, 2014, 77, 18-37.	2.6	21
83	Expression of domains for proteinâ€“protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 817-824.	0.9	7
84	SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research, 2014, 20, 4574-4583.	3.2	258
85	Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leukemia and Lymphoma, 2014, 55, 188-190.	0.6	11
86	Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatographyâ€“tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406, 2925-2941.	1.9	32
87	In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells. Tumor Biology, 2014, 35, 8991-8998.	0.8	6
88	Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2â€²-deoxyuridine-5â€²-monophosphate on ABCC11 in silico models. BMC Structural Biology, 2013, 13, 7.	2.3	11
89	Identification and characterization of inhibitors of cytoplasmic 5â€²-nucleotidase cN-II issued from virtual screening. Biochemical Pharmacology, 2013, 85, 497-506.	2.0	29
90	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€“control study in the context of the IMMEnSE consortium. Journal of Human Genetics, 2013, 58, 155-159.	1.1	5

#	Article	IF	Citations
91	Bortezomib influences the expression of malignant plasma cells membrane antigens. European Journal of Pharmacology, 2013, 706, 11-16.	1.7	12
92	3â€Arylâ€4â€methylâ€2â€quinolones Targeting Multiresistant Staphylococcus aureus Bacteria. ChemMedChem, 2013, 8, 652-657.	1.6	32
93	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Reviews Drug Discovery, 2013, 12, 447-464.	21.5	925
94	Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells. Molecular Pharmacology, 2013, 84, 12-24.	1.0	80
95	Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?. Biomarkers in Medicine, 2013, 7, 663-671.	0.6	16
96	Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. Clinical Cancer Research, 2013, 19, 3556-3566.	3.2	14
97	Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. Molecular Cancer Therapeutics, 2013, 12, 2031-2042.	1.9	301
98	Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate, 2013, 73, 1738-1746.	1.2	31
99	Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.	0.1	0
100	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1782-1791.	13.9	1,022
101	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. British Journal of Haematology, 2012, 158, 805-809.	1.2	19
102	Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction. PLoS ONE, 2012, 7, e51329.	1.1	60
103	A labelâ€free mass spectrometry method for relative quantitation of Î²â€tubulin isotype expression in human tumor tissue. Proteomics - Clinical Applications, 2012, 6, 502-506.	0.8	4
104	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, 664-674.e6.	0.6	218
105	Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. International Journal of Antimicrobial Agents, 2012, 39, 444-447.	1.1	34
106	Progesteroneâ€“adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. Steroids, 2012, 77, 1177-1191.	0.8	8
107	Le microbiome intestinal influence-t-il le dÃ©veloppement des hÃ©patocarcinomes ?. Bulletin Du Cancer, 2012, 99, 1105-1106.	0.6	0
108	Synthesis and Evaluation of a Molecularly Imprinted Polymer for Selective Solid-Phase Extraction of Irinotecan from Human Serum Samples. Journal of Functional Biomaterials, 2012, 3, 131-142.	1.8	8

#	Article	IF	Citations
109	Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth. Cancer Research, 2012, 72, 4429-4439.	0.4	67
110	Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investigational New Drugs, 2012, 30, 1121-1131.	1.2	105
111	Prognostic value of PINI index in patients with multiple myeloma. European Journal of Haematology, 2012, 88, 306-313.	1.1	22
112	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the <scp>IMME</scp>n<scp>SE</scp> consortium. British Journal of Haematology, 2012, 157, 331-338.	1.2	13
113	Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 342-349.	0.2	9
114	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncology, The, 2011, 12, 693-702.	5.1	147
115	Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside. SIAM Journal on Applied Mathematics, 2011, 71, 2246-2268.	0.8	24
116	Les anticorps thÃ©rapeutiques bispÃ©cifiques : deux fois plus puissants ?. Bulletin Du Cancer, 2011, 98, 1381-1382.	0.6	0
117	Inhibition of IGF-1 Signalling Enhances the Apoptotic Effect of AS602868, an IKK2 Inhibitor, in Multiple Myeloma Cell Lines. PLoS ONE, 2011, 6, e22641.	1.1	18
118	Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, 2011, 117, 1673-1676.	0.6	51
119	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). International Journal of Oncology, 2011, 40, 625-38.	1.4	14
120	Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncology Reports, 2011, 25, 1161-7.	1.2	9
121	Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. Cancer Chemotherapy and Pharmacology, 2011, 68, 97-105.	1.1	4
122	Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survivalâ€"A retrospective study of 42 adult cases. Leukemia Research, 2011, 35, 1027-1031.	0.4	7
123	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Molecular Cancer Therapeutics, 2011, 10, 178-185.	1.9	125
124	Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 303-312.	1.9	10
125	MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors. International Journal of Breast Cancer, 2011, 2011, 1-6.	0.6	6
126	Structural Insights into the Inhibition of Cytosolic 5â€²-Nucleotidase II (cN-II) by Ribonucleoside 5â€²-Monophosphate Analogues. PLoS Computational Biology, 2011, 7, e1002295.	1.5	24

#	Article	IF	Citations
127	Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches. Current Drug Metabolism, 2011, 12, 268-277.	0.7	13
128	Transfection of cells in suspension by ultrasound cavitation. Journal of Controlled Release, 2010, 142, 251-258.	4.8	43
129	Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. BMC Cancer, 2010, 10, 135.	1.1	23
130	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer, 2010, 126, 545-562.	2.3	110
131	Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: A review. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1912-1928.	1.2	49
132	Design, synthesis and evaluation of progesteroneâ€“adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3165-3168.	1.0	6
133	Primary cutaneous marginal zone lymphoma. Critical Reviews in Oncology/Hematology, 2010, 74, 156-162.	2.0	37
134	Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews Drug Discovery, 2010, 9, 790-803.	21.5	1,431
135	BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. Clinical Cancer Research, 2010, 16, 3988-3997.	3.2	37
136	The role of Î²III tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer, 2010, 67, 136-143.	0.9	71
137	Potent and Fully Noncompetitive Peptidomimetic Inhibitor of Multidrug Resistance P-Glycoprotein. Journal of Medicinal Chemistry, 2010, 53, 6720-6729.	2.9	26
138	Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplantation, 2010, 45, 1316-1324.	1.3	38
139	Beta-tubulin III expression in prostate cancer. Scandinavian Journal of Urology and Nephrology, 2010, 44, 371-377.	1.4	16
140	Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 661-665.	0.9	13
141	Dysregulation of Ribosome Biogenesis and Translational Capacity Is Associated with Tumor Progression of Human Breast Cancer Cells. PLoS ONE, 2009, 4, e7147.	1.1	198
142	ADP Ribosylation Factor Like 2 (Arl2) Regulates Breast Tumor Aggressivity in Immunodeficient Mice. PLoS ONE, 2009, 4, e7478.	1.1	22
143	Ixabepilone: targeting Î²III-tubulin expression in taxane-resistant malignancies. Molecular Cancer Therapeutics, 2009, 8, 17-25.	1.9	109
144	Triptolide is an inhibitor of RNA polymerase I and IIâ€“dependent transcription leading predominantly to down-regulation of short-lived mRNA. Molecular Cancer Therapeutics, 2009, 8, 2780-2790.	1.9	152

#	Article	IF	Citations
145	Reply to L.C. Panasci. Journal of Clinical Oncology, 2009, 27, e112-e113.	0.8	0
146	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology, 2009, 42, 87-103.	1.1	65
147	Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs, 2009, 1, 222-229.	2.6	47
148	Bacterial Deoxyribonucleoside Kinases are Poor Suicide Genes in Mammalian Cells. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 1068-1075.	0.4	2
149	Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. Journal of Clinical Oncology, 2009, 27, 1168-1176.	0.8	461
150	Reply to R.S. Mehta et al. Journal of Clinical Oncology, 2009, 27, 3068-3069.	0.8	1
151	In vivoModel of Follicular Lymphoma Resistant to Rituximab. Clinical Cancer Research, 2009, 15, 851-857.	3.2	36
152	Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla. FÃ¬toterapÃ¬Ã¢, 2009, 80, 39-42.	1.1	34
153	Î²3â€tubulin is induced by estradiol in human breast carcinoma cells through an estrogenâ€receptor dependent pathway. Cytoskeleton, 2009, 66, 378-388.	4.4	23
154	Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III Î²â€tubulin. Journal of Cellular Physiology, 2009, 221, 505-513.	2.0	59
155	Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta-cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2009, 63, 11-16.	1.6	6
156	Development of a sensitive and selective LC/MS/MS method for the simultaneous determination of intracellular 1-beta-d-arabinofuranosylcytosine triphosphate (araCTP), cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in a human follicular lymphoma cell line. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1417-1425.	1.2	32
157	Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2937-2944.	1.2	33
158	Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3831-3840.	1.2	65
159	Characterization of an inhibitory dynamic pharmacophore for the ERCC1â€“XPA interaction using a combined molecular dynamics and virtual screening approach. Journal of Molecular Graphics and Modelling, 2009, 28, 113-130.	1.3	36
160	Special feature of mixed phosphotriester derivatives of cytarabine. Bioorganic and Medicinal Chemistry, 2009, 17, 6340-6347.	1.4	28
161	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. European Journal of Gastroenterology and Hepatology, 2009, 21, 245-253.	0.8	22
162	Preparation, Characterization and <I>In Vitro</I> Evaluation of a New Nucleotide Analogue Prodrug Cyclodextrin Inclusion Complexes. Journal of Nanoscience and Nanotechnology, 2009, 9, 295-300.	0.9	2

#	Article	IF	Citations
163	Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. Cancer, 2008, 112, 572-580.	2.0	42
164	Antimitotic and Antiproliferative Activities of Chalcones: Forward Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 2008, 51, 2307-2310.	2.9	166
165	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and geneâ€expression levels. Cancer Science, 2008, 99, 1992-2003.	1.7	66
166	High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. British Journal of Haematology, 2008, 143, 54-59.	1.2	18
167	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor Â expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocrine-Related Cancer, 2008, 15, 125-138.	1.6	30
168	Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochemical and Biophysical Research Communications, 2008, 375, 308-314.	1.0	42
169	Expression of excision repair cross-complementation group 1 and class III Î²-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer, 2008, 62, 105-112.	0.9	40
170	Is class III Î²-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncology, The, 2008, 9, 168-175.	5.1	275
171	Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. Clinical Leukemia, 2008, 2, 198-204.	0.2	11
172	Paclitaxel-Loaded Microparticles for Intratumoral Administration via the TMT Technique: Preparation, Characterization, and Preliminary Antitumoral Evaluation. Drug Development and Industrial Pharmacy, 2008, 34, 698-707.	0.9	22
173	Class III Î²-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research, 2008, 14, 4511-4516.	3.2	58
174	Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle, 2008, 7, 3074-3082.	1.3	27
175	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood, 2008, 112, 3154-3163.	0.6	47
176	Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice.. Blood, 2008, 112, 1585-1585.	0.6	8
177	Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Research, 2008, 28, 1161-7.	0.5	17
178	Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 708-715.	0.6	81
179	Class III Î²-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Nonâ€“Small Cell Lung Cancer: Analysis of NCIC JBR.10. Clinical Cancer Research, 2007, 13, 994-999.	3.2	138
180	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myèlome. Blood, 2007, 109, 3489-3495.	0.6	845

#	Article	IF	Citations
181	A revised nomenclature for the human and rodent Î±-tubulin gene family. Genomics, 2007, 90, 285-289.	1.3	60
182	Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia. Cancer Letters, 2007, 250, 117-127.	3.2	15
183	Nucleoside analogue delivery systems in cancer therapy. Expert Opinion on Drug Delivery, 2007, 4, 513-531.	2.4	23
184	The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer, 2007, 109, 292-299.	2.0	136
185	Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1776, 138-159.	3.3	46
186	ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Experimental Cell Research, 2007, 313, 473-485.	1.2	33
187	Class III Î²-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemotherapy and Pharmacology, 2007, 60, 27-34.	1.1	45
188	Structureâ€“activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorganic and Medicinal Chemistry, 2006, 14, 6979-6987.	1.4	54
189	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 2006, 108, 3289-3294.	0.6	639
190	Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 163-170.	0.8	22
191	Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5700-5703.	1.0	12
192	F-ara-AMP is a substrate of cytoplasmic 5â€²-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. Nucleosides, Nucleotides and Nucleic Acids, 2006, 25, 289-297.	0.4	13
193	Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 547-554.	1.1	33
194	The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. Cancer, 2006, 106, 2058-2066.	2.0	51
195	Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer, 2006, 107, 2698-2705.	2.0	100
196	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. International Journal of Cancer, 2006, 119, 60-66.	2.3	10
197	Ungueotropic T-Cell Lymphoma. Archives of Dermatology, 2006, 142, 1065.	1.7	13
198	A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. Bulletin Du Cancer, 2006, 93, E115-8.	0.6	1

#	Article	IF	Citations
199	Unusual Organisms in the Bone Marrow of a Patient With Systemic Sarcoidosis. Laboratory Medicine, 2005, 36, 762-763.	0.8	0
200	Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood, 2005, 105, 767-774.	0.6	70
201	Chemoresistance in Non-Small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 73-88.	7.0	129
202	Expression of Class III Î²-Tubulin Is Predictive of Patient Outcome in Patients with Nonâ€“Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy. Clinical Cancer Research, 2005, 11, 5481-5486.	3.2	193
203	Class III Î²-tubulin expression in tumor cells predicts response and outcome in patients with nonâ€“small cell lung cancer receiving paclitaxel. Molecular Cancer Therapeutics, 2005, 4, 2001-2007.	1.9	224
204	Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Molecular Cancer Therapeutics, 2005, 4, 1268-1276.	1.9	57
205	Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leukemia and Lymphoma, 2005, 46, 335-346.	0.6	18
206	cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer, 2005, 49, 363-370.	0.9	62
207	Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin Du Cancer, 2005, 92, E25-30.	0.6	42
208	The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica, 2005, 90, 1699-701.	1.7	34
209	Structure-Activity Relationships for Euphocharacins A - L, a New Series of Jatrophane Diterpenes, as Inhibitors of Cancer Cell P-Glycoprotein. Planta Medica, 2004, 70, 657-665.	0.7	34
210	Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line. Clinical Cancer Research, 2004, 10, 5614-5621.	3.2	60
211	The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. Clinical Cancer Research, 2004, 10, 6956-6961.	3.2	360
212	Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. The Hematology Journal, 2004, 5, 403-409.	2.0	11
213	Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene, 2004, 23, 2287-2297.	2.6	26
214	Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacology, 2004, 4, 8.	0.4	62
215	Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia. Leukemia and Lymphoma, 2004, 45, 1123-1132.	0.6	60
216	Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). Leukemia and Lymphoma, 2004, 45, 711-714.	0.6	29

#	Article	IF	Citations
217	Jatrophane Diterpenes as Modulators of Multidrug Resistance. Advances of Structureâ^'Activity Relationships and Discovery of the Potent Lead Pepluanin A. Journal of Medicinal Chemistry, 2004, 47, 988-992.	2.9	87
218	Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones. Journal of Medicinal Chemistry, 2004, 47, 4964-4970.	2.9	65
219	Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 1361-1365.	0.8	27
220	5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. Haematologica, 2004, 89, 617-9.	1.7	8
221	In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochemical Pharmacology, 2003, 66, 2185-2191.	2.0	24
222	Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine. Biochemical Pharmacology, 2003, 65, 121-129.	2.0	22
223	Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. International Journal of Cancer, 2003, 107, 149-154.	2.3	20
224	Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L.. Bioorganic and Medicinal Chemistry, 2003, 11, 5221-5227.	1.4	36
225	Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. British Journal of Haematology, 2003, 122, 53-60.	1.2	83
226	A New P-Glycoprotein Inhibitor from the Caper Spurge (Euphorbia lathyris). Journal of Natural Products, 2003, 66, 140-142.	1.5	57
227	Pyrimidine nucleoside analogs in cancer treatment. Expert Review of Anticancer Therapy, 2003, 3, 717-728.	1.1	51
228	Jatrophane Diterpenes as P-Glycoprotein Inhibitors. First Insights of Structureâ^'Activity Relationships and Discovery of a New, Powerful Lead. Journal of Medicinal Chemistry, 2003, 46, 3395-3402.	2.9	79
229	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. Leukemia and Lymphoma, 2003, 44, 257-262.	0.6	29
230	Role of IMP-SELECTIVE 5â€²-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES. Leukemia and Lymphoma, 2003, 44, 1105-1111.	0.6	28
231	Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Annals of Oncology, 2003, 14, 615-622.	0.6	8
232	A Two-complementary Method Assay for Screening New Reversal Agents of Cancer Cell Multidrug Resistance. Pharmaceutical Biology, 2003, 41, 72-77.	1.3	2
233	In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood, 2003, 102, 1549-1550.	0.6	49
234	Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. Clinical Breast Cancer, 2002, 3, 341-345.	1.1	74

#	Article	IF	Citations
235	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. Clinical Lymphoma and Myeloma, 2002, 3, 41-47.	2.1	148
236	Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncology, The, 2002, 3, 415-424.	5.1	494
237	Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Medicinal Research Reviews, 2002, 22, 512-529.	5.0	158
238	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. International Journal of Cancer, 2002, 97, 439-445.	2.3	92
239	Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes To Cells, 2002, 7, 29-39.	0.5	76
240	In vivomechanisms of resistance to cytarabine in acute myeloid leukaemia. British Journal of Haematology, 2002, 117, 860-868.	1.2	144
241	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. British Journal of Haematology, 2002, 118, 210-217.	1.2	25
242	Potential mechanisms of resistance to cytarabine in AML patients. Leukemia Research, 2002, 26, 621-629.	0.4	125
243	Isoprenoid flavonoids are new leads in the modulation of chemoresistance. Phytochemistry Reviews, 2002, 1, 325-332.	3.1	19
244	Recent Advances in the Discovery of Flavonoids and Analogues with Highâ€Affinity Binding to Pâ€Glycoprotein Responsible for Cancer Cell Multidrug Resistance. ChemInform, 2002, 33, 257-257.	0.1	1
245	Thalidomide in patients with advanced multiple myeloma: a study of 83 patientsâ€“report of the intergroupe francophone du myÃ©lome (IFM). The Hematology Journal, 2002, 3, 185-192.	2.0	71
246	C-Isoprenylation of Flavonoids Enhances Binding Affinity toward P-Glycoprotein and Modulation of Cancer Cell Chemoresistance. Journal of Medicinal Chemistry, 2001, 44, 763-768.	2.9	108
247	Expression of high Km 5â€²-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood, 2001, 98, 1922-1926.	0.6	80
248	The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. British Journal of Haematology, 2001, 112, 405-409.	1.2	28
249	Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology, 2001, 113, 772-778.	1.2	90
250	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood, 2000, 95, 802-806.	0.6	484
251	Mechanisms of action and resistance to tubulin-binding agents. Expert Opinion on Investigational Drugs, 2000, 9, 779-788.	1.9	39
252	Thalidomide in patients with advanced multiple myeloma. The Hematology Journal, 2000, 1, 186-189.	2.0	32

#	Article	IF	Citations
253	Transient Acute Myopia Induced by Antilymphocyte Globulins. Ophthalmologica, 1999, 213, 133-134.	1.0	10
254	Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Annals of the Rheumatic Diseases, 1999, 58, 335-341.	0.5	96
255	Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology, 1999, 106, 78-85.	1.2	125
256	Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. American Journal of Medicine, 1999, 106, 191-197.	0.6	45
257	Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death. Journal of Clinical Oncology, 1999, 17, 1061-1061.	0.8	524
258	Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562. Advances in Experimental Medicine and Biology, 1999, 457, 571-577.	0.8	12
259	Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. British Journal of Haematology, 1998, 103, 235-241.	1.2	144
260	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. Blood, 1998, 91, 3148-3155.	0.6	186
261	Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins. Journal of Biological Chemistry, 1997, 272, 5974-5982.	1.6	74
262	Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. Journal of Immunological Methods, 1997, 206, 115-123.	0.6	9
263	Differential expression of tubulin isotypes during the cell cycle. , 1996, 35, 49-58.		29
264	Early Diagnosis of Ventilator-Associated Pneumonia. Chest, 1996, 110, 1558-1565.	0.4	49
265	IL-3 increases marrow and peripheral erythroid precursors in chronic pure red cell aplasia presenting in childhood. British Journal of Haematology, 1995, 89, 413-416.	1.2	8
266	Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833. Journal of the National Cancer Institute, 1995, 87, 1593-1602.	3.0	80
267	Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. Cancer Immunology, Immunotherapy, 1994, 38, 311-316.	2.0	19
268	Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity. Journal of Pediatrics, 1992, 121, 78-80.	0.9	16
269	Kinetics and organ distribution of [14C]-sialic acid-GM3 and [3H]-sphingosine-GM1 after intravenous injection in rats. Biochemical and Biophysical Research Communications, 1992, 189, 1410-1416.	1.0	17
270	Silicosis due to inhalation of domestic cleaning powder. Lancet, The, 1991, 338, 1085.	6.3	18

#	Article	IF	Citations
271	Acute Silicosis Due to Inhalation of a Domestic Product. The American Review of Respiratory Disease, 1991, 143, 880-882.	2.9	24
272	Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. American Journal of Medicine, 1990, 88, 13-20.	0.6	67
273	Human T-cell leukemia virus type I-induced proliferation of human thymocytes requires the presence of a comitogen. Cellular Immunology, 1988, 112, 391-401.	1.4	6